Alder’s mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. As a licensing partner, Alder is also revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics.
Initial Public Offering (NASDAQ: ALDR) in May 2014.
Amnis is developing high-throughput laboratory automation tools that use a novel molecule detection technology. The Amnis platform has both molecular and cellular-based applications in research and the clinic.
Acquired by EMD Millipore, the Life Science division of Merck KGaA, in August 2011.
Corus Pharma develops pharmaceutical products that address unmet needs in infectious disease and respiratory disorders.
Acquired by Gilead Sciences, Inc. in August 2006.
Seattle-based C-SATS, Inc. is a venture-backed healthcare technology company on a mission to empower the nation's 16 million healthcare workers and institutions to assess and improve their performance continuously, accurately and objectively. Developed at the University of Washington, our scalable software utilizes a unique combination of distributed experts and extra-institutional reviewers to assess technical performance with accuracy equivalent to gold standards. It's Crowd-Sourced Assessment of Technical Skills...or C-SATS.
Acquired by Johnson & Johnson in April 2018.
Decide's e-commerce service finds the lowest prices for a vast range of consumer electronics and offers predictions on new model releases and future price changes.
Acquired by eBay in September 2013.
EKOS is developing technologies that use localized ultrasound to facilitate, enhance or control the delivery or activation of drugs at a targeted tissue site.
Acquired by BTG in May 2013.
This University of Washington startup uses a combination of techniques to find patterns in the variation of airline ticket prices over time and so predict future price movements. The method may also apply to hotel rooms, rental cars and other analogous markets.
Acquired by Microsoft in April 2008.
GlobeImmune is a biopharmaceutical company developing targeted molecular immunogens (Tarmogens) for the treatment of cancer and infectious diseases.
Initial Public Offering (NASDAQ: GBIM) in July 2014.
HaloSource, Inc. is a bioscience company that employs chitin/chitosan and N-halamine-based technologies to serve the water treatment, biomedical, home and personal care markets.
Initial Public Offering (LSE: HALO.L) in October 2010.
Intelligent Ion is developing a miniature mass spectrometer based on proprietary technologies developed at the University of Washington and California Institute of Technology/Jet Propulsion Laboratory.
Assets and intellectual property were acquired by O.I. Corp. in December 2004.
Lumera develops electro-photonic components based on proprietary polymer materials licensed from the University of Washington.
Initial Public Offering (NasdaqNM: LMRA) in 2004.
Mirador Biomedical is developing disposable medical devices that provide data to physicians during common medical procedures to eliminate preventable complications and make the procedures safer.
Acquired by Centurion Medical Products in October 2014.
Mobisante, Inc. is a privately held mHealth product and services company. Their goal is to make ultrasound imaging more affordable and accessible to help health care professionals practice better medicine and to reduce costs.
Acquired by Renew Group in November 2015
Nimbic (formerly Physware) helps customers solve their signal integrity (SI), power integrity (PI) and EMI challenges in a variety of design areas including microprocessors, FPGAs, memory, wireless RF systems, analog systems, and high-speed serial and parallel channels.
Acquired by Mentor Graphics Corp. in May 2014
Numinous Technologies was founded in 1996 to develop graphics and interactive video software. Among its founders are noted computer graphics scientists David Salesin of the University of Washington and Andries van Dam of Brown University.
Acquired by Microsoft in March 1999.
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.
Initial Public Offering (NasdaqNM: OMER) in October 2009.
Pacific Bioscience Laboratories, Inc., a Washington company incorporated in 2001, is the developer of the Clarisonic™ Skin Care System, a range of devices that use sonic waves to enable users to achieve healthier, younger-looking skin.
Acquired by L’Oréal in December 2011.
Pathway Medical Technologies, Inc. was founded to develop, manufacture and market medical devices for the treatment of arterial disease. The company’s initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies.
Acquired by MEDRAD, Inc., an affiliate of Bayer HealthCare, in August 2011.
Performant is developing leading-edge technology to optimize back-end performance of enterprise computer systems. The company’s OptiBench product suite will enable customers to completely outsource the management of their information technology system’s performance.
Acquired by Mercury Interactive in May 2003.
RBL is developing standards-based educational curriculum and assessment tools delivered through the internet. The RBL software is based on 35 years of study by Norris Haring, a founding director of the EEU Center on Human Development and Disability at the University of Washington.
Acquired by McGraw-Hill Education in April 2002.